959983-12-1

Upstream product

• 959983-11-0 1,1-dimethylethyl (8-cyclohexyl-5-((((dimethylamino)sulfonyl)amino)carbonyl)-11-(methyloxy)-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl)carbamate 
• 494799-18-7 methyl 3-cyclohexyl-1H-indole-6-carboxylate 
• 494799-17-6 3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid 
• 494799-16-5 3-(cyclohex-1-en-1-yl)-1H-indole-6-carboxylic acid 
• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 494799-76-7 2-bromo-3-cyclohexyl-1H-indole-6-carboxylic acid 
• 1670-82-2 Indole-6-carboxylic acid 
• 959983-22-3 cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, (+/-)- 
• 959983-21-2 cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, methyl ester, (+/-)- 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 902148-53-2 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxamide 
• 902148-54-3 13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid methyl ester 
• 928844-26-2 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-1H-indole-6-carboxamide 
• 959983-23-4 8-cyclohexyl-5-(((dimethylamino)sulfonyl)carbamoyl)-11-methoxy-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a(2H)-carbonyl azide 

Downstream Products

• 1045705-05-2 8-cyclohexyl-N-((dimethylamino)sulfonyl)-11-(methyloxy)-1a-((4-morpholinyl(oxo)acetyl)amino)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1045705-30-3 8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-((4-morpholinylsulfonyl)amino)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 

Relevant academic research and scientific papers

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The invention encompasses compounds as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.